Henssler, Jonathan ORCID: 0000-0001-8123-5853, Alexander, David, Schwarzer, Guido ORCID: 0000-0001-6214-9087, Bschor, Tom and Baethge, Christopher (2022). Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression A Systematic Review and Meta-analysis. JAMA Psychiatry, 79 (4). S. 300 - 313. CHICAGO: AMER MEDICAL ASSOC. ISSN 2168-6238

Full text not available from this repository.

Abstract

IMPORTANCE Combining antidepressants is frequently done in the treatment of acute depression, but studies have yielded conflicting results. OBJECTIVE To conduct a systematic review and meta-analysis assessing efficacy and tolerability of combination therapy. Combinations using presynaptic alpha 2-autoreceptor antagonists or bupropion were investigated separately. DATA SOURCES MEDLINE, Embase, PsycINFO, and the Cochrane Central Register of Controlled Trials were systematically searched from each database inception through January 2020. STUDY SELECTION Randomized clinical trials (RCTs) comparing combinations of antidepressants with antidepressant monotherapy in adult patients with acute depression were included. DATA EXTRACTION AND SYNTHESIS Following guidelines from Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and recommendations from the Cochrane Handbook, 2 reviewers independently performed a literature search, study selection, data extraction, and evaluation of risk of bias. Data were pooled in random-effects analyses. MAIN OUTCOMES AND MEASURES Primary outcome was efficacy measured as standardized mean difference (SMD); secondary outcomes were response, remission, change from baseline in rating scale scores, number of dropouts, and number of dropouts due to adverse events. RESULTS Thirty-nine RCTs including 6751 patients were eligible. Combination treatment was statistically significantly associated with superior treatment outcomes relative to monotherapy (SMD = 0.31; 95% CI, 0.19-0.44). Combining a reuptake inhibitor with an antagonist of presynaptic a2-autoreceptors was superior to other combinations (SMD = 0.37; 95% CI, 0.19-0.55). Bupropion combinations were not superior to monotherapy (SMD = 0.10; 95% CI, -0.07 to 0.27). Numbers of dropouts and dropouts due to adverse events did not differ between treatments. Studies were heterogeneous, and there was indication of publication bias (Egger test result was positive; P = .007, df = 36), but results remained robust across prespecified secondary outcomes and sensitivity and subgroup analyses, including analyses restricted to studies with low risk of bias. CONCLUSIONS AND RELEVANCE In this meta-analysis of RCTs comparing combinations of antidepressants with antidepressant monotherapy, combining antidepressants was associated with superior treatment outcomes but not with more patients dropping out of treatment. Combinations using an antagonist of presynaptic alpha 2-autoreceptors may be preferable and may be applied as a first-line treatment in severe cases of depression and for patients considered nonresponders.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Henssler, JonathanUNSPECIFIEDorcid.org/0000-0001-8123-5853UNSPECIFIED
Alexander, DavidUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schwarzer, GuidoUNSPECIFIEDorcid.org/0000-0001-6214-9087UNSPECIFIED
Bschor, TomUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Baethge, ChristopherUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-684437
DOI: 10.1001/jamapsychiatry.2021.4313
Journal or Publication Title: JAMA Psychiatry
Volume: 79
Number: 4
Page Range: S. 300 - 313
Date: 2022
Publisher: AMER MEDICAL ASSOC
Place of Publication: CHICAGO
ISSN: 2168-6238
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
RESISTANT MAJOR DEPRESSION; DOUBLE-BLIND; ADD-ON; AUGMENTATION; FLUOXETINE; EFFICACY; MIANSERIN; COMBINATION; DISORDER; MIRTAZAPINEMultiple languages
PsychiatryMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/68443

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item